Highlights
- TPM203, an innovative nanoparticle platform, demonstrates a favorable safety profile with no serious adverse events in its first-in-human Phase I trial.
- The therapy utilizes liver sinusoidal endothelial cells (LSECs) to promote antigen-specific tolerance by delivering immunodominant desmoglein 3 (Dsg3) peptides.
- Pharmacodynamic results reveal a significant increase in regulatory T (Treg) cells and a reduction in Th17.1 and memory B-cell subsets.
- Preclinical and early clinical data suggest a reduction in anti-Dsg3 IgG-induced keratinocyte dissociation, indicating potential for disease modification.
Background
Pemphigus vulgaris (PV) is a severe, potentially life-threatening autoimmune blistering disease of the skin and mucous membranes. The pathophysiology is driven by IgG autoantibodies, primarily directed against desmoglein 3 (Dsg3) and desmoglein 1 (Dsg1), which are critical desmosomal adhesion proteins. This antibody-mediated interference leads to acantholysis—the loss of cell-to-cell adhesion between keratinocytes. Current therapeutic strategies rely heavily on systemic corticosteroids and B-cell depleting agents like rituximab. While effective, these treatments cause broad immunosuppression, increasing the risk of opportunistic infections and other long-term morbidities. Therefore, a significant unmet need exists for therapies that can induce antigen-specific immune tolerance without compromising the host’s overall immune competence.
The concept of using the liver as a primary site for tolerance induction has gained traction in recent years. Liver sinusoidal endothelial cells (LSECs) possess a unique capacity to present antigens in a tolerogenic context, promoting the development of regulatory T cells (Tregs) and the deletion of effector T cells. TPM203 represents a pioneering application of this biological principle, utilizing biodegradable nanoparticles to deliver Dsg3-derived peptides specifically to these hepatic pathways.
Key Content
Preclinical Foundations and Mechanism of Action
Before entering human trials, the efficacy of TPM203 was rigorously evaluated in a humanized mouse model. These mice were transgenic for HLA-DRB1*0402, an MHC class II allele strongly associated with PV susceptibility in humans. In this model, the administration of TPM203 resulted in a marked reduction of anti-Dsg3 IgG titers. At the cellular level, research observed a significant decrease in splenic CD4+ T-cell populations and a reciprocal increase in Treg frequencies. This suggested that the nanoparticle delivery system effectively redirected the immune response from a pathogenic effector state toward a stable regulatory state.
Phase I Clinical Trial Design (EudraCT 2019-001727-12)
The clinical development of TPM203 progressed to an open-label, first-in-human Phase I study. The trial enrolled 17 patients diagnosed with PV who exhibited no-to-moderate disease activity. The study was structured into two main components: Single Ascending Dose (SAD) and Multiple Dose (MD) cohorts. Patients in the MD group received three intravenous doses of TPM203 at two-week intervals. The primary focus of this early-phase investigation was to establish safety and tolerability, while secondary and exploratory endpoints evaluated pharmacokinetics (PK) and pharmacodynamics (PD).
Safety and Pharmacokinetic Profile
One of the most significant outcomes of the Phase I trial was the clean safety profile of TPM203. No serious or severe adverse events (AEs) were reported, and no patients experienced a treatment-related worsening of their PV symptoms. From a pharmacokinetic perspective, TPM203 was cleared rapidly from the systemic circulation, which is consistent with the targeted uptake of nanoparticles by the liver’s reticuloendothelial system and LSECs. This rapid clearance minimizes the risk of off-target effects in peripheral tissues.
Pharmacodynamic Effects and Immune Modulation
The exploratory PD endpoints provided compelling evidence of immune reprogramming. When analyzing combined dose groups, researchers identified several key shifts in the peripheral lymphocyte landscape:
- T-cell Polarization: A significant increase in bulk Treg populations was observed, alongside a decrease in T helper 17.1 (Th17.1) cells, which are often associated with chronic inflammatory states.
- B-cell Memory: There was a notable reduction in CD27+ memory B cells, which are the precursors to autoantibody-producing plasma cells.
- Antigen Specificity: Dsg3-specific T cells showed a significant decline by week 8 following a single administration, suggesting that the tolerizing effect was indeed directed toward the autoantigenic driver of the disease.
- Functional Improvement: Perhaps most promisingly, the keratinocyte-dissociating capacity of the patients’ IgG was significantly reduced after multiple doses of TPM203. This indicates that even if total IgG levels remain present, the pathogenicity of the autoantibodies may be diminished or the autoantibody profile shifted toward less harmful subclasses.
Expert Commentary
The results of the TPM203 Phase I trial mark a pivotal moment in the transition from broad immunosuppression to targeted “immune resetting” in dermatology. The ability to induce tolerance via LSEC-mediated pathways avoids the risks associated with global T-cell or B-cell depletion. Mechanistically, the increase in Tregs and reduction in Th17.1 cells align with the classical models of peripheral tolerance. However, some questions remain regarding the durability of this effect. While Dsg3-specific T cells were reduced at week 8, long-term follow-up will be necessary to determine if periodic “booster” doses of nanoparticles are required to maintain tolerance.
Furthermore, the reduction in keratinocyte dissociation capacity despite only a modest downward trend in total anti-Dsg3 IgG suggests a qualitative change in the antibody repertoire. This could involve an “epitope spreading” reversal or a shift in IgG subclass (e.g., from IgG4 to a non-pathogenic subclass), a phenomenon that warrants deeper investigation in Phase II trials. The primary limitation of the current study is its small sample size and open-label nature, which are standard for Phase I but necessitate cautious interpretation regarding clinical efficacy.
Conclusion
TPM203 has successfully navigated its first-in-human trial, proving to be safe, well-tolerated, and biologically active. By demonstrating the ability to modulate both the T-cell and B-cell arms of the autoimmune response in Pemphigus Vulgaris, this nanoparticle platform opens the door for a new class of “tolerogens.” Future research should focus on dose optimization in larger Phase II cohorts and expanding the platform to other autoimmune blistering diseases where specific autoantigens are well-characterized. If successful, TPM203 could redefine the standard of care, moving the field closer to a curative rather than a purely management-based approach for PV.
References
- Didona D, Hudemann C, Garn H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus. Br J Dermatol. 2026;194(1):86-98. PMID: 40795222.
